16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements
Key Takeaways
KDOQI 2020 was developed jointly by the National Kidney Foundation and the Academy of Nutrition and Dietetics and covers adults with CKD stages 1–5, 5D and post-transplant.
Level 1 statements read 'we recommend' and Level 2 statements 'we suggest'; evidence is graded A (high) to D (very low); ungraded OPINION statements reflect expert consensus.
KDOQI 2020 recommends the 7-point Subjective Global Assessment for adults on dialysis (1B) and suggests a 3-day food record covering dialysis and non-dialysis days (2C).
KDOQI 2020 suggests at least a 3-month trial of oral nutritional supplements before escalation, and a trial of IDPN for maintenance hemodialysis patients with PEW whose needs are not met orally or enterally (2C).
KDOQI 2020 finds insufficient evidence to recommend plant versus animal protein (1B) and suggests not routinely supplementing zinc or selenium (2C).
Why this guideline anchors the exam
The KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update (Ikizler et al., American Journal of Kidney Diseases 2020;76(3 Suppl 1)) replaced the 2000 KDOQI nutrition guideline. It was a joint project of the National Kidney Foundation (NKF) and the Academy of Nutrition and Dietetics, whose Evidence Analysis Center ran the systematic reviews. The Academy also publishes it on the Evidence Analysis Library (EAL) as the CKD evidence-based nutrition practice guideline. The CSR outline names "nutrition guidelines (e.g., AND, KDOQI, KDIGO)" in Domain 3. A task statement asks you to utilize evidence-based protocols and guidelines (i.e., KDOQI) to deliver standardized care.
The guideline covers adults with CKD stages 1–5, stage 5D (on dialysis) and post-transplant. It does not cover children, and it leaves many areas to clinical judgment where evidence is thin.
How statements are graded
KDOQI 2020 used the GRADE method:
- Strength: Level 1, "we recommend", means most patients should receive the course of action and it could serve as a performance measure. Level 2, "we suggest", means different choices suit different patients and shared decision-making is expected.
- Quality of evidence: A (high), B (moderate), C (low), D (very low).
- OPINION: an ungraded statement written when evidence was absent or too weak but the work group judged guidance important. It usually describes routine practice ("it is reasonable to…").
So "1A" is a strong recommendation on high-quality evidence, "2C" is a weak suggestion on low-quality evidence, and OPINION is expert consensus.
Key statements by guideline area
1. Nutrition assessment
| Statement | Grade |
|---|---|
| Routine nutrition screening at least biannually in CKD 3–5D or post-transplant | OPINION |
| Comprehensive assessment by an RDN within the first 90 days of dialysis, annually, or when screening or a referral indicates | OPINION |
| Bioimpedance (preferably multi-frequency) in maintenance HD, done at least 30 minutes after the session | 2C |
| DXA as the gold standard for body composition despite volume effects | OPINION |
| Weight and BMI at least monthly on dialysis, every 3 months in CKD 4–5 or post-transplant, every 6 months in CKD 1–3 | OPINION |
| BMI alone is not enough to diagnose PEW unless it is very low (below 18 kg/m²) | OPINION |
| Serum albumin predicts hospitalization and mortality in maintenance HD | 1A |
| Handgrip strength as an indicator of protein-energy and functional status when baseline data exist | 2B |
| 7-point SGA is valid and reliable for adults on dialysis | 1B |
| Malnutrition Inflammation Score may be used in maintenance HD or post-transplant | 2C |
| 3-day food record covering dialysis and non-dialysis days as the preferred intake method | 2C |
| Assess factors beyond intake: medications, knowledge, beliefs, food access, depression, cognition | OPINION |
2. Medical nutrition therapy
- An RDN, in close collaboration with a physician or other provider, should provide MNT in CKD 1–5D to improve nutrition status and slow progression (1C).
- MNT should be tailored and monitored through appetite, intake, weight, labs, anthropometrics and physical findings (OPINION).
3. Protein and energy
| Population | Statement | Grade |
|---|---|---|
| CKD 3–5, metabolically stable, no diabetes | LPD 0.55–0.60 g/kg/day, or VLPD 0.28–0.43 g/kg/day plus ketoacid or amino acid analogues (to meet 0.55–0.60), under close supervision | 1A (ESKD/death); 2C (quality of life) |
| CKD 3–5 with diabetes | 0.6–0.8 g/kg/day | OPINION |
| Maintenance HD or PD, metabolically stable | 1.0–1.2 g/kg/day | 1C (HD); OPINION (PD) |
| Dialysis with diabetes | 1.0–1.2 g/kg/day, possibly higher to help glycemic control | OPINION |
| CKD 1–5D or post-transplant, stable | Energy 25–35 kcal/kg/day | 1C |
| Protein type | Insufficient evidence to recommend plant versus animal protein | 1B |
| Dietary pattern | Mediterranean diet may improve lipids (CKD 1–5 and post-transplant) | 2C |
| Dietary pattern | More fruits and vegetables may lower weight, BP and net acid production (CKD 1–4) | 2C |
4. Nutritional supplementation
- Oral supplements: at least a 3-month trial for patients at risk of or with PEW when counseling alone does not meet needs (2D).
- Enteral tube feeding: a trial is reasonable when intake stays inadequate despite counseling and oral supplements (OPINION).
- TPN or IDPN: a trial of TPN in CKD 1–5 and IDPN in maintenance HD for PEW when needs cannot be met orally or enterally (2C).
- Amino acid dialysate (PD): not suggested as a general strategy, but a trial is reasonable when needs cannot be met otherwise (OPINION).
- Long-chain omega-3s: not routinely prescribed to lower mortality or cardiovascular events in HD (2C/2B) or to improve access patency. They may be used at 1.3–4 g/day to lower triglycerides in HD (2C).
5. Micronutrients
- Encourage a diet meeting the RDA for vitamins and minerals. Consider a multivitamin when intake is inadequate; on dialysis, supplement water-soluble vitamins and essential trace elements if intake stays poor (OPINION).
- Folate: do not routinely supplement to lower homocysteine (1A, no cardiovascular benefit), but do correct folate or B12 deficiency (2B).
- Vitamin C: for patients at risk of deficiency, supplementing to at least 90 mg/day (men) or 75 mg/day (women) is reasonable (OPINION).
- Vitamin D: correct 25(OH)D deficiency with cholecalciferol or ergocalciferol (2C).
- Vitamins A and E: do not routinely supplement on dialysis because of toxicity risk (OPINION).
- Vitamin K: no vitamin K supplements for patients on warfarin-type anticoagulants (OPINION).
- Zinc and selenium: do not routinely supplement (2C).
6. Electrolytes
| Topic | Statement | Grade |
|---|---|---|
| Acid load | Increase fruit and vegetable intake to reduce net acid production in CKD 1–4 | 2C |
| Bicarbonate | Reduce net acid production with bicarbonate or citrate supplements in CKD 3–5D | 1C |
| Bicarbonate target | Keep serum bicarbonate at 24–26 mmol/L | OPINION |
| Calcium | Total elemental calcium 800–1,000 mg/day (diet, supplements and calcium binders) in CKD 3–4 not on active vitamin D | 2B |
| Phosphorus | Adjust dietary phosphorus to keep serum phosphate in the normal range (CKD 3–5D) | 1B |
| Phosphorus source | Consider bioavailability (animal, vegetable, additives) | OPINION |
| Post-transplant hypophosphatemia | High-phosphorus diet or supplements | OPINION |
| Potassium | Adjust intake to keep serum potassium normal; individualize for hyper- or hypokalemia | OPINION; 2D |
| Sodium | Less than 100 mmol/day (below 2.3 g/day) to lower BP and improve volume control | 1B (CKD 3–5); 1C (5D and post-transplant) |
| Sodium and proteinuria | The same limit reduces proteinuria alongside medications (CKD 3–5) | 2A |
Applying the guideline
- Grades guide confidence, not rigidity. A 1A statement (protein restriction in stable CKD 3–5) is strong. An OPINION (bicarbonate 24–26 mmol/L) is expert practice that other bodies may differ on; KDIGO 2024 suggests treating acidosis when bicarbonate is below about 18 mmol/L.
- The guideline deliberately avoids fixed milligram limits for potassium and phosphorus, which marks a shift from older "renal diet" numbers.
- Know the populations. Diabetes, dialysis modality and transplant status change the protein statements.
- Pair it with KDIGO for topics KDOQI 2020 does not cover, such as anemia drugs, MBD drugs and AKI (see section 16.2).
A statement in the KDOQI 2020 nutrition guideline ends with the grade '2C.' How should a renal dietitian interpret it?
A strong recommendation based on high-quality evidence that should apply to nearly all patients.
An ungraded expert-consensus statement written because no studies existed.
A weak suggestion ('we suggest') based on low-quality evidence, where individual choices may reasonably differ.
A regulatory requirement that surveyors enforce under the Conditions for Coverage.
A hemodialysis unit starts using multi-frequency bioimpedance to assess body composition. Which practice follows KDOQI 2020?
Measure at least 30 minutes after the end of the hemodialysis session to allow fluid redistribution.
Measure during the first 10 minutes of dialysis while blood flow is stable.
Measure immediately after the blood lines are disconnected.
Stop using bioimpedance, because KDOQI recommends against it in maintenance hemodialysis.
A maintenance hemodialysis patient with protein-energy wasting has had dietary counseling for 6 weeks without meeting protein and energy needs. According to KDOQI 2020, what is the next step?
Start IDPN immediately, because it is the first-line nutrition support for all hemodialysis patients with PEW.
Stop nutrition intervention, because KDOQI 2020 found no benefit from supplementation.
Replace dialysate dextrose with amino acid dialysate.
Begin oral nutritional supplements, allowing at least a 3-month trial before judging them, and consider IDPN only if oral and enteral intake still cannot meet requirements.
Sections you finish are checked off in the contents.